Articles

Videos

Podcasts

Clinical

The oral PARP inhibitor is associated with increased PFS, regardless of BRCA mutational status.

Niraparib as First-Line Maintenance Treatment of Ovarian, Fallopian Tube, Primary Peritoneal Cancer

Bevacizumab-maly (Almysys; mAbxience) is the third biosimilar of bevacizumab (Avastin) approved in the United States.

Third Biosimilar to Bevacizumab Granted FDA Approval

Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.

Rucaparib Shows Efficacy Across Tumors Associated With Different Genetic Alterations 

Rucaparib (Rubraca) significantly improved progression-free survival when administered as maintenance treatment in newly diagnosed patients with advanced ovarian cancer.

Rucaparib Found to Significantly Improve Progression-Free Survival in Ovarian Cancer 

ImmunoGen, Inc submits Biologics License Application under the accelerated approval pathway for mirvetuximab soravtansine monotherapy for patients with FRα-high platinum-resistant ovarian cancer previously treated with 1 to 3 prior systemic treatments.

BLA Submitted for Mirvetuximab Soravtansine in Ovarian Cancer

Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Clincial Trials Show Niraparib Improves PFS With Tolerable Safety Profile Following Response to Platinum-based Chemotherapy in Ovarian Cancer

Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer. 

PARP Inhibitors Play Important Role in Frontline, Recurrent Maintenance Treatment of Ovarian Cancer

Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.

Approaching Treatment of Newly Diagnosed or Recurrent Ovarian Cancer With PARP Inhibitors 

Data from the SOLO-1 trial highlight that even with an excellent prognostic group, patients with ovarian cancer still benefit from the use of a PARP inhibitor.

Assessing Therapeutic Approach to Treatment-Naïve Advanced Ovarian Cancer

Use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer resulted in meaningful anti-tumor activity, consistent safety, and favorable tolerability.

Pivotal Trial Supports Use of Mirvetuximab Soravtansine in Ovarian Cancer

® Ovarian Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to the group of diseases that originates in the ovaries, fallopian tubes, or the peritoneum.